A clinical-stage biopharmaceutical company developing therapies for breast cancer, with its lead programs focused on the drug candidate endoxifen for treatment and prevention settings. The firm operates without commercialized products and relies on clinical trial progress and regulatory milestones t...
1 member of Congress has disclosed 1 trade in Atossa Therapeutics, Inc. (ATOS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-10-25 | Roger W. Marshall | buy | $1K – $15K |